Natixis Arrowhead Pharmaceuticals, Inc. Transaction History

Natixis

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$27.21 - $39.48 $5.55 Million - $8.05 Million	204,000 New	204,000 $5.83 Million
Q4 2022 Feb 24, 2023	BUY	$28.0 - $40.56 $114,912 - $166,458	4,104 New	4,104 $166,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $1.13 Million - $1.61 Million	-19,486 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $1.14 Million - $1.66 Million	19,486 New	19,486 $1.22 Million
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $3.56 Million - $5.25 Million	-58,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$43.82 - $85.37 $1.67 Million - $3.26 Million	38,130 Added 191.9%	58,000 $4.45 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $1.27 Million - $1.95 Million	-38,130 Reduced 65.74%	19,870 $856,000
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $1.3 Million - $2.16 Million	49,840 Added 610.78%	58,000 $2.51 Million
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $1.01 Million - $3.1 Million	-49,167 Reduced 85.77%	8,160 $235,000
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $1.61 Million - $4.19 Million	57,327 New	57,327 $3.68 Million

293

90.6M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.98B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.